138Pd_Pr Patient-reported outcomes (Pros) in Alex: A phase Iii study of alectinib (Alec) vs crizotinib (Criz) in non-small-cell lung cancer (Nsclc)
Perol, M.; Peters, S.; Pavlakis, N.; Levchenko, E.; Platania, M.; Oliveira, J.; Novello, S.; Karagiannis, T.; Zeaiter, A.; Dziadziuszko, R.
Journal of Thoracic Oncology 13(4): S80-S81
2018
ISSN/ISBN: 1556-0864
DOI: 10.1016/s1556-0864(18)30412-x
Accession: 067146898
PDF emailed within 0-6 h: $19.90
Related References
Pérol, M.; Pavlakis, N.; Levchenko, E.; Platania, M.; Oliveira, J.; Novello, S.; Chiari, R.; Moran, T.; Mitry, E.; Nüesch, E.; Liu, T.; Balas, B.; Konopa, K.; Peters, S. 2019: Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer Lung Cancer 138: 79-87Kim, Y; Hida, T; Nokihara, H; Kondo, M; Azuma, K; Seto, T; Takiguchi, Y; Nishio, M; Yoshioka, H; Imamura, F; Hotta, K; Watanabe, S; Goto, K; Nakagawa, K; Mitsudomi, T; Yamamoto, N; Kuriki, H; Asabe, R; Tanaka, T; Tamura, T 2017: MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX) Journal of Thoracic Oncology 12(1): S378-S379
Bordoni, R.; Ciardiello, F.; Von Pawel, J.; Cortinovis, D.; He, P.; Karagiannis, T.; Ballinger, M.; Sandler, A.; Yu, W.; Felizzi, F.; Rittmeyer, A. 2017: P1.01-052 Patient-Reported Outcomes (Pros) in Oak: A Phase Iii Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (Nsclc) Journal of Thoracic Oncology 12(11): S1914-S1915
Hida, T.; Nokihara, H.; Kondo, M.; Kim, Y.Hak.; Azuma, K.; Seto, T.; Takiguchi, Y.; Nishio, M.; Yoshioka, H.; Imamura, F.; Hotta, K.; Watanabe, S.; Goto, K.; Satouchi, M.; Kozuki, T.; Shukuya, T.; Nakagawa, K.; Mitsudomi, T.; Yamamoto, N.; Asakawa, T.; Asabe, R.; Tanaka, T.; Tamura, T. 2017: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Lancet 390(10089): 29-39
Hotta, K.; Hida, T.; Nokihara, H.; Morise, M.; Kim, Y.H.; Azuma, K.; Seto, T.; Takiguchi, Y.; Nishio, M.; Yoshioka, H.; Kumagai, T.; Watanabe, S.; Goto, K.; Satouchi, M.; Kozuki, T.; Shukuya, T.; Nakagawa, K.; Mitsudomi, T.; Yamamoto, N.; Asakawa, T.; Yoshimoto, T.; Takata, S.; Tamura, T. 2022: Final overall survival analysis from the phase IIi J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer Esmo Open 7(4): 100527
Peters, S.; Shaw, A.T.; Besse, B.; Felip, E.; Solomon, B.J.; Soo, R.A.; Bearz, A.; Gadgee, S.M.; Lin, C-C.; Kao, S.; Seto, T.; Masters, E.T.; Abbattista, A.; Clancy, J.S.; Thurm, H.; Reisman, A.; Camidge, D.R. 2018: Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii504-Viii505
Wu, Y.; Chang, J.; Zhang, L.; Tu, H.; Wu, L.; Feng, J.; Lu, S.; Zhou, C.; Wang, J.; Mok, T.; Taylor, F.; Mossman, B.; Penrod, J.; Lawrance, R.; Blum, S. 2018: Oa10 Check Mate 078: Patient-Reported Outcomes (Pros) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (Nsclc) Journal of Thoracic Oncology 13(12): S1047-S1048
Nishio, M.; Nakagawa, K.; Mitsudomi, T.; Yamamoto, N.; Tanaka, T.; Kuriki, H.; Zeaiter, A.; Tamura, T. 2018: Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Lung Cancer 121: 37-40
Nishio, M; Nakagawa, K; Mitsudomi, T; Yamamoto, N; Tanaka, T; Kuriki, H; Zeaiter, A; Tamura, T 2018: Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK -positive non-small-cell lung cancer Lung Cancer 121: 37-40
Nakagawa, K.; Hida, T.; Nokihara, H.; Morise, M.; Azuma, K.; Kim, Y.H.; Seto, T.; Takiguchi, Y.; Nishio, M.; Yoshioka, H.; Kumagai, T.; Hotta, K.; Watanabe, S.; Goto, K.; Satouchi, M.; Kozuki, T.; Koyama, R.; Mitsudomi, T.; Yamamoto, N.; Asakawa, T.; Hayashi, M.; Hasegawa, W.; Tamura, T. 2020: Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Lung Cancer 139: 195-199
Zhou, C.; Lu, Y.; Kim, S-W.; Reungwetwattana, T.; Zhou, J.; Zhang, Y.; He, J.; Yang, J-J.; Cheng, Y.; Lee, S.H.; Bu, L.; Xu, T.; Yang, L.; Wang, C.; Morcos, P.N.; Mitry, E.; Li, Z. 2018: Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 9: Ix174
Gadgeel, S.; Peters, S.; Mok, T.; Shaw, A.T.; Kim, D.W.; Ou, S.I.; Pérol, M.; Wrona, A.; Novello, S.; Rosell, R.; Zeaiter, A.; Liu, T.; Nüesch, E.; Balas, B.; Camidge, D.R. 2018: Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study Annals of Oncology: Official Journal of the European Society for Medical Oncology 29(11): 2214-2222
Kuruvilla, P.G.; Krieger, H.; Zibdawi, L.; Meharchand, J.; Solow, H.; Leighl, N.; Chin, C.; Stewart, J.A.; Hollen, P.J.; Gralla, R.J. 2016: Assessing quality of life (QL) and patient reported outcomes (PROs) in clinical trials and clinical practice: A study using a hand-held computerized form of the validated LCSS instrument in patients with non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 23(16_Suppl): 8067-8067
Gainor, J.F.; Shaw, A.T. 2017: J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer Lancet 390(10089): 3-4
Ou, S.-H.I.; Ahn, J.S.; De Petris, L.; Govindan, R.; Yang, J.C.-H.; Hughes, B.; Lena, H.é; Moro-Sibilot, D.; Bearz, A.; Ramirez, S.V.; Mekhail, T.; Spira, A.; Bordogna, W.; Balas, B.; Morcos, P.N.; Monnet, A.; Zeaiter, A.; Kim, D.-W. 2016: Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: a Phase Ii Global Study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34(7): 661-668